Inclusion Criteria:  Subjects who have signed the informed consent Subjects with a confirmed medical history of asthma (intermittent or persistent mild-moderate, controlled), as defined by GEMA 5 with rhinitis/ rhinoconjunctivitis (intermittent or persistent) according to the ARIA classification caused by polysensitization to grass pollen and mites (D.pteronyssinus and / or D. farinae). The diagnosis of asthma will be valid from 24 months prior to signing the informed consent. Subjects with a positive prick test (major diameter of the papule ≥ to 5 mm) to a standardized extract of grass pollen mixture, or to one of the components of the mixture (Dactilys glomerata, Poa pratensis, Holcus lanatus, Festuca elatior, Phleum pratense and Lolium perenne) and to an extract of D. pteronyssinus and / or D. farinae. Specific IgE (CAP or Immulite) against one of the components of the mixture of grasses, preferably Phleum pratense or a mixture of grasses and mites (D. pteronyssinus and / or D. farinae) or one or more of the molecular components of allergenic sources with a value > 3,5 KU / L. Subjects aged between 18 and 65 years. Subjects capable of complying with the dosing regimen. Women of childbearing age (from menarche) should submit a urine pregnancy test with a negative result at the time of enrolment in the trial. Women of childbearing potential and men participating in the trial should commit to using an adequate method of contraception. Medically acceptable methods of contraception are intrauterine devices placed at least 3 months in advance, surgical sterilization (for example, tubal ligation), barrier methods, or the use of oral contraceptives. Subjects who have a smartphone to record symptoms and medication.  Exclusion Criteria:  Subjects who have received prior immunotherapy treatment in the preceding 5 years for any of the allergens tested or a cross-reactive allergen or are currently receiving immunotherapy with any aeroallergen. Subjects sensitized to other aeroallergens other than grass or mites pollen belonging to the genus Dermatophagoides, with the exception of epithelia as long as the subject has occasional exposure and symptoms. Patients in whom immunotherapy may be the object of an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee cannot be included. Subjects with severe or uncontrolled asthma, and / or with a FEV1 <70% with respect to the reference value despite adequate pharmacological treatment at the time of inclusion in the trial. Subjects who have previously presented a serious secondary reaction during the performance of diagnostic skin tests using the prick test. Subjects under treatment with ß-blockers. Subjects under treatment with immunosuppressive or biological drugs. Clinically unstable subjects at the time of inclusion in the trial (respiratory infection, feverish process, acute urticaria, etc.). Subjects with chronic urticaria in the past 2 years, severe anaphylaxis, or a history of hereditary angioedema. Subjects who have any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, HT, heart disease, etc.). Subjects with some other disease not related to moderate rhinoconjunctivitis or asthma, but of potential severity and that may interfere with treatment and follow-up (epilepsy, psychomotor disorder, diabetes, malformations, subjects who underwent multiple surgeries, kidney disease...), according to investigator's criteria. Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumour diseases or with a diagnosis of immunodeficiencies. Subject whose condition prevents him / her from offering cooperation and or who presents severe psychiatric disorders, according to investigator criteria. Subjects with known allergies to other investigational product components other than grass pollen or mites. Subjects with diseases of the lower respiratory tract other than asthma such as emphysema or bronchiectasis. Pregnant or lactating women.